Dabrafenib is a reversible, ATP-competitive kinase inhibitor that targets the MAPK pathway, indicated for the treatment of various cancers harboring BRAF V600 mutations, including metastatic melanoma,… Read more



















Dabrafenib is a reversible, ATP-competitive kinase inhibitor that targets the MAPK pathway, indicated for the treatment of various cancers harboring BRAF V600 mutations, including metastatic melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. This category provides essential reference standards for the parent drug, alongside its related compounds, such as pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these materials to perform robust impurity profiling, verify compound identity, and ensure accurate quantification during analytical testing. These reference standards are critical for rigorous method validation and quality control procedures, enabling laboratories to monitor degradation products and manufacturing by-products throughout the drug development lifecycle. By facilitating precise benchmarking, these compounds support adherence to regulatory requirements and help maintain the integrity and consistency of pharmaceutical formulations.